DE102008025751A1 - New 4-(1H-pyrrolo(2,3-b)pyridin-3-yl)-pyridin-2-yl-amine derivatives are serine kinase modulators, useful to treat solid tumors, tumor growth, tumor metastasis, AIDS, occlusive neointimal lesions, arteriosclerosis, coronary artery disease - Google Patents

Abstract

4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-yl-amine derivatives (I) and their salts, tautomers, stereoisomers, and subsequently their mixtures in all ratios are new. 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-yl-amine derivatives of formula (I) and their salts, tautomers, stereoisomers, and subsequently their mixtures in all ratios are new. R 1>H, A, -[C(R 6>) 2] nAr 1>, -[C(R 6>) 2] nHet, -[C(R 6>) 2] ncycloalkyl, COA, COAr 1>, CON(R 6>) 2or CON(R 6>)Ar 1>; R 2>H, A or -[C(R 6>) 2] nAr 1>; R 3>H, A, OR 6>, N(R 6>) 2, -[C(R 6>) 2] nAr 1>, -[C(R 6>) 2] nHet, -[C(R 6>) 2] ncycloalkyl, O[C(R 6>) 2] nN(R 6>) 2or O[C(R 6>) 2] nHet; R 4>H, A, Hal, CN, -[C(R 6>) 2] nAr 1>, -[C(R 6>) 2] nHet, -[C(R 6>) 2] ncycloalkyl, OR 6>or N(R 6>) 2; R 5>, R 6>H or 1-6C-alkyl; A : 1-10C-alkyl, in which one or two CH 2groups are optionally substituted by O or S atoms and/or -CH=CH-groups and/or 1-7 H atoms are optionally substituted by F, or cyclic cycloalkyl 3-7C-alkyl, which is substituted replaced by 1-6C-alkyl; Hal : F, Cl, Br or I; Ar 1>phenyl optionally 1-3 times substituted by Hal, A, OR 6>, N(R 6>) 2, NO 2, CN, COOR 6>, CON(R 6>) 2, NR 6>COA, NR 6>SO 2A, COR 6>, SO 2N(R 6>) 2and/or S(O) pA; Het : optionally 1 or 2 times saturated or aromatic heterocycle with 1-4 N, O and/or S, which is optionally 1 or 2 times substituted by H, A, OR 6>, N(R 6>) 2, NO 2, CN, COOR 6>, CON(R 6>) 2, NR 6>COA, NR 6>SO 2A, COR 6>, SO 2N(R 6>) 2, S(O) pA and/or =O; n : 0-4; and p : 0-2. Independent claims are included for: (1) the preparation of (I); and (2) the use of (I) for the preparation of a medicament to treat tumors, tumor growth, tumor metastasis and/or AIDS. [Image] ACTIVITY : Cytostatic; Anti-HIV; Antiarteriosclerotic; Cardiant; Vasotropic; Antiarthritic; Osteopathic. MECHANISM OF ACTION : Serine kinase modulator; Threonine kinase modulator.

Description

worin
R¹ H, A, -[C(R⁶)₂]_nAr, -[C(R⁶)₂]_nHet, -[C(R⁶)₂]_nCycloalkyl, COA, COAr, CON(R⁶)₂ oder CON(R⁶)Ar,
R² H, A oder -[C(R⁶)₂]_nAr,
R³ H, A, OR⁶, N(R⁶)₂, -[C(R⁶)₂]_nAr, -[C(R⁶)₂]_nHet, -[C(R⁶)₂]_nCycloalkyl, O(C(R⁶)₂]_nN(R⁶)₂ oder O[C(R⁶)₂]_nHet,
R⁴ H, A, Hal, CN, -[C(R⁶)₂]_nAr, -[C(R⁶)₂]_nHet, -[C(R⁶)₂]_nCycloalkyl, OR⁶ oder N(R⁶)₂
R⁵ H oder Alkyl mit 1-6 C-Atomen,
R⁶ H oder Alkyl mit 1-6 C-Atomen,
A unverzweigtes oder verzweigtes Alkyl mit 1-10 C-Atomen, worin eine oder zwei CH₂-Gruppen durch O- oder S-Atome und/oder durch -CH=CH-Gruppen und/oder auch 1-7 H-Atome durch F ersetzt sein können,
Cycloalkyl Cyclisches Alkyl mit 3-7 C-Atomen, das zusätzlich durch Alkyl mit 1-6 C-Atomen substituiert sein kann,
Hal F, Cl, Br oder I,
Ar unsubstituiertes oder ein-, zwei- oder dreifach durch Hal, A, OR⁶, N(R⁶)₂, NO₂, CN, COOR⁶, CON(R⁶)₂, NR⁶COA, NR⁶SO₂A, COR⁶, SO₂N(R⁶)₂ und/oder S(O)_pA substituiertes Phenyl,
Het einen unsubstituierten oder ein- oder zweifach durch Hal, A, OR⁶, N(R⁶)₂, NO₂, CN, COOR⁶, CON(R⁶)₂, NR⁶COA, NR⁶SO₂A, COR⁶, SO₂NR⁶, S(O)_pA und/oder =O (Carbonylsauerstoff) substituierten ein- oder zweikernigen gesättigten, ungesättigten oder aromatischen Heterocyclus mit 1 bis 4 N-, und/oder O- und/oder S-Atomen,
n 0, 1, 2, 3 oder 4,
p 0, 1 oder 2
bedeuten,
sowie ihre pharmazeutisch verwendbaren Salze, Tautomere und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.The invention relates to compounds of the formula I.

wherein
R ^{1 is} H, A, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _n cycloalkyl, COA, COAr, CON (R ⁶ ) ₂ or CON (R ⁶ ) Ar,
R ^{2 is} H, A or - [C (R ⁶ ) ₂ ] _n Ar,
R ^{3 is} H, A, OR ⁶ , N (R ⁶ ) ₂ , - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _n Cycloalkyl, O (C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ or O [C (R ⁶ ) ₂ ] _n Het,
R ^{4 is} H, A, Hal, CN, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _n cycloalkyl, OR ⁶ or N (R ⁶ ) ₂
R ^{5 is} H or alkyl having 1-6 C atoms,
R ^{6 is} H or alkyl having 1-6 C atoms,
A is unbranched or branched alkyl having 1-10 C atoms, in which one or two CH ₂ groups by O or S atoms and / or by -CH = CH groups and / or also 1-7 H atoms by F can be replaced
Cycloalkyl Cyclic alkyl having 3-7 C atoms, which may additionally be substituted by alkyl having 1-6 C atoms,
Hal F, Cl, Br or I,
Ar is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ⁶ , N (R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ⁶ COA, NR ⁶ SO ₂ A, COR ⁶ , SO ₂ N (R ⁶ ) ₂ and / or S (O) _p A substituted phenyl,
Het an unsubstituted or mono- or disubstituted by Hal, A, OR ⁶ , N (R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ⁶ COA, NR ⁶ SO ₂ A, COR ⁶ , SO ₂ NR ⁶ , S (O) _p A and / or = O (carbonyl oxygen) substituted mono- or binuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 N-, and / or O and / or S atoms,
n 0, 1, 2, 3 or 4,
p 0, 1 or 2
mean,
and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.

Of the Invention was based on the object, new compounds with valuable Find properties, especially those for the production of medicines can be used.

It has been found that the compounds of formula I and their Salts with good compatibility very valuable pharmacological Own properties.

Especially show an inhibiting effect of cell proliferation / cell vitality as antagonists or agonists. The invention Compounds can therefore be used to control and / or Treatment of tumors, tumor growth and / or tumor metastasis used become. The antiproliferative effect may be in a proliferation assay / vitality assay be tested.

Amino-pyrimidinyl derivatives are in WO 2006/050076 and from PM Fresneda et al. in Tetrahedron 57 (2001) 2355-2363 described.

Accordingly be the compounds of the invention or a pharmaceutically acceptable salt thereof for the treatment administered by cancer, including solid carcinomas, such as carcinomas (eg, the lungs, the pancreas, the Thyroid, bladder or colon), myeloid Diseases (eg myeloid leukemia) or adenomas (eg. Villous colon adenoma).

To the tumors continue to include monocyte leukemia, Brain, urogenital, lymphatic, gastric, laryngeal and lung carcinoma, including lung adenocarcinoma and small cell lung carcinoma, pancreatic and / or breast carcinoma.

The Compounds are also useful in the treatment of immunodeficiency induced by HIV-1 (human immunodeficiency virus type 1).

When cancerous hyperproliferative diseases are brain cancer, lung cancer, Squamous cell cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, Kidney cancer, colorectal cancer, breast cancer, head cancer, cervical cancer, esophageal cancer, gynecological cancer, thyroid cancer, lymphoma, chronic leukemia and acute leukemia. In particular, cancerous cell growth is a disease that an object of the present invention. Subject of the present Invention are therefore compounds of the invention as drugs and / or drugs in the treatment and / or prophylaxis of said diseases and use of compounds of the invention for the preparation a pharmaceutical for the treatment and / or prophylaxis the said diseases as well as a method of treatment the said diseases comprising the administration of one or a plurality of inventive compounds to a Patients in need of such administration.

It can be shown that the invention Compounds have antiproliferative activity. The invention Compounds are given to a patient with a hyperproliferative Administered disease, z. To inhibit tumor growth, for the reduction of those associated with a lymphoproliferative disorder Inflammation, to inhibit graft rejection or neurological damage due to tissue repair etc. The present compounds are useful for prophylactic or therapeutic purposes. As used herein The term "treating" is used as a reference both on the prevention of diseases as well as the treatment of pre-existing ones Suffering used. The prevention of proliferation / vitality is administered by administration of the invention Links reached before development of the obvious disease, z. To prevent tumor growth. As an alternative, the Compounds for the treatment of persistent diseases by stabilization or improvement of the patient's clinical symptoms.

Of the The host or patient may be of any mammalian species, z. A primate species, especially humans; Including rodents Mice, rats and hamsters; Rabbits; Horses, cattle, Dogs, cats, etc. Animal models are for experimental Investigations of interest, being a model for treatment to provide a human disease.

The Susceptibility of a particular cell the treatment with the compounds according to the invention can be determined by testing in vitro. Typically will a culture of the cell with an inventive Compound at different concentrations for a period of time incubated sufficient to allow the active agents Induce cell death or cell proliferation, cell vitality or to inhibit migration, usually between about an hour and a week. For testing in vitro cultured cells from a biopsy sample can be used. The Amount remaining after treatment remaining cells then determined.

The Dose varies depending on the specific used Connection, specific disease, patient status, etc. Typically, one therapeutic dose is sufficient to treat the unwanted cell population in the target tissue significantly increased diminish while maintaining the patient's viability becomes. The treatment is generally continued until a significant Reduction is present, for. B. at least about 50% reduction in cell load and can be continued until essentially no unwanted Cells are detected more in the body.

It There are many with a deregulation of cell proliferation and the Cell death (apoptosis) associated diseases. The suffering of interest include, but are not limited to, the following ailments limited. The compounds of the invention are useful in treating a variety of ailments, in which proliferation and / or migration of smooth muscle cells and / or inflammatory cells in the intimal layer of a vessel present, resulting in limited blood flow this vessel, z. B. in neointimal occlusive Lesions. To occlusive graft vascular disease Of interest include atherosclerosis, coronary vascular disease after transplantation, vein graft stenosis, peri-anastomotic denture restenosis, Restenosis after angioplasty or stent placement and the like.

The compounds of formula I, also act as regulators, modulators or inhibitors of prote incinases, in particular of the serine / threonine kinase type.

By Protein kinase-induced diseases are characterized by an abnormal Activity or hyperactivity of such protein kinases characterized. Abnormal activity concerns either: (1) expression in cells, usually these protein kinases do not express; (2) increased kinase expression, the leads to unwanted cell proliferation, such as cancer; (3) increased kinase activity leading to unwanted Cell proliferation, such as cancer, and / or hyperactivity of the corresponding protein kinases leads. hyperactivity refers either to an amplification of the gene, the one certain protein kinase, or the generation of an activity level, which can be correlated with a cell proliferative disease (i.e., as the kinase level increases, the severity of one or more increases multiple symptoms of cell proliferation disease) the biological Availability of a protein kinase may also be due to the presence or lack of a set of binding proteins of this kinase become.

The most important cancers using an inventive Compound can treat, include colorectal cancer, small cell lung cancer, non-small cell lung cancer, the multiple Myeloma and renal cell carcinoma and endometrial carcinoma, bersonders also cancers in which PTEN is mutated, u. a. breast cancer Prostate cancer and glioblastoma.

moreover can the compounds of the invention used to treat certain existing cancer chemotherapies and irradiations to achieve additive or synergistic effects and / or the effectiveness of certain existing cancer chemotherapies and irradiations.

Under Compounds of the formula I are also understood as meaning the hydrates and solvates these compounds, and pharmaceutically acceptable derivatives. The invention also relates to the optically active forms (stereoisomers), Salts, the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Among solvates of the compounds become deposits of inert solvent molecules understood by the connections that are due to their mutual Train attraction. Solvates are z. As mono- or dihydrates or alcoholates.

Under pharmaceutically usable derivatives are understood z. As the salts the compounds of the invention as well as so-called Prodrug compounds.

Under Prodrug derivatives are understood with z. B. alkyl or acyl groups, Sugars or oligopeptides modified compounds of the formula I, which in the organism rapidly to the effective compounds of the invention be split.

These include biodegradable polymer derivatives of the compounds of the invention, as z. In Int. J. Pharm. 115, 61-67 (1995) is described.

Of the Expression "effective amount" means the amount of one Medicinal product or a pharmaceutical active substance containing a biological or medical response in a tissue, system, animal or causes people who z. B. by a researcher or physician sought or desired.

Moreover, the term "therapeutically effective amount" means an amount that, as compared to a corresponding subject who has not received that amount, results in:
improved curative treatment, cure, prevention or elimination of a disease, a clinical picture, a disease state, a condition, a disorder or side effects or even a reduction in the progression of a disease, a condition or a disorder.

The Term "therapeutically effective amount" also the amounts that are effective, the normal physiological Increase function.

object The invention also relates to the use of mixtures of the compounds the formula I, z. B. mixtures of two diastereomers z. B. in proportion 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1: 100 or 1: 1000.

Especially These are preferably mixtures of stereoisomeric compounds.

• a) eine Verbindung der Formel II
  
  worin R eine Schutzgruppe bedeutet, R³, R⁴ und R⁵ die in Anspruch 1 angegebenen Bedeutungen haben, mit einer Verbindung der Formel III R¹-NH₂ IIIworin R¹ A, -[C(R⁶)₂]_nAr, -[C(R⁶)₂]_nCycloalkyl oder -[C(R⁶)₂]_nHet bedeutet, und Ar, Cycloalkyl, Het, R⁶ und n die in Anspruch 1 angegebenen Bedeutungen haben, umsetzt, und gleichzeitig oder anschließend die Schutzgruppe R abspaltet, oder
• b) eine Verbindung der Formel IV
  
  worin R eine Schutzgruppe bedeutet, R⁴ und R⁵ die in Anspruch 1 angegebenen Bedeutungen haben, zuerst in einer Masuda-Kupplung zu einer Bor-Verbindung umsetzt und anschließend in einer Suzuki-Kupplung mit einer Verbindung der Formel V
  
  worin R¹ und R³ die in Anspruch 1 angegebenen Bedeutungen haben, umsetzt, und gleichzeitig oder anschließend die Schutzgruppe R abspaltet, und/oder eine Base oder Säure der Formel I in eines ihrer Salze umwandelt.

The invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claims 1-13 and their pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, characterized in that

• a) a compound of formula II
  
  wherein R is a protective group, R ³ , R ⁴ and R ^{5 have} the meanings given in claim 1, with a compound of formula III R ¹ -NH ₂ III wherein R ^{1 is} A, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _{n is} cycloalkyl or - [C (R ⁶ ) ₂ ] _n Het, and Ar, cycloalkyl, Het, R ⁶ and n have the meanings given in claim 1, and simultaneously or subsequently the protective group R is split off, or
• b) a compound of formula IV
  
  wherein R is a protecting group, R ⁴ and R ^{5 have} the meanings given in claim 1, first reacted in a Masuda coupling to a boron compound and then in a Suzuki coupling with a compound of formula V
  
  wherein R ¹ and R ^{3 have} the meanings given in claim 1, and simultaneously or subsequently the protective group R is split off, and / or converts a base or acid of the formula I into one of its salts.

Above and below, the radicals R ¹ , R ² , R ³ , R ⁴ and R ^{5 have} the meanings given for the formula I, unless expressly stated otherwise.

A is alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C-Ato me. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, more preferably e.g. B. trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or 1,1,1-trifluoroethyl. In A, one or two CH ₂ groups may be replaced by O or S atoms and / or by -CH = CH groups. So A means z. As well as 2-methoxy-ethyl.

cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

Ar means z. Phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-methylsulfonylphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-methylaminophenyl, o-, m- or p-dimethylaminophenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-methylaminosulfonylphenyl, o-, m- or p-aminocarbonylphenyl, o-, m- or p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-formylphenyl, o-, m- or p-cyanophenyl, more preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, p-iodophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl or 2,5-dimethyl-4-chlorophenyl.

Ar is preferably unsubstituted or mono-, di- or trisubstituted by Hal and / or OR ⁶ phenyl.

Het irrespective of further substitutions, e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferred 1,2,3-triazole-1, -4- or -5-yl, 1,2,4-triazole-1, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4 or 5-yl, 1,2,4-oxadiazol-3 or -5-yl, 1,3,4-thiadiazol-2 or -5-yl, 1,2,4-thiadiazole-3 or -5-yl, 1,2,3-thiadiazol-4 or -5-yl, 3- or 4-pyridazinyl, Pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl, more preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4 or 5-yl or 2,1,3-benzoxadiazol-5-yl.

The Heterocyclic radicals may also be partially or completely be hydrogenated.

unsubstituted Het can so z. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2-or 3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2-or 3-thienyl, 2,3-dihydro-1, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or 4-imidazolyl, 2,3-dihydro-1, -2, -3, -4 or 5-pyrazolyl, Tetrahydro-1-, 3- or 4-pyrazolyl, 1,4-dihydro-1-, 2-, -3- or 4-pyridyl, 1,2,3,4-tetrahydro-1-, 2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxane-2-, -4- or -5-yl, Hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or 5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, 2, 3, 4, 5, 6, 7 or 8-quinolyl, 1,2,3,4-tetrahydro-1, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo [1,4] oxazinyl, more preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4- (difluoromethylenedioxy) phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3- (2-oxo-methylenedioxy) -phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6 or -7-yl, further preferred 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl.

Het further preferably means an unsubstituted or a or mono- or binuclear aromatic substituted by A Heterocycle having 1 to 4 N, and / or O and / or S atoms.

Het more preferably means unsubstituted or mono- or di-double A substituted furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, Oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, Tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, Benzimidazolyl, indazolyl, quinolyl or 1,3-benzodioxolyl.

R ¹ is preferably H, A or - [C (R ⁶ ) ₂ ] _n Ar.

R ¹ particularly preferably denotes H, phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o -, m- or p-methoxyphenyl, 4-fluoro-3-chlorophenyl, methyl, ethyl, propyl, butyl or pentyl.

R ² is preferably H.

R ³ is preferably H or N (R ⁶ ) ₂ .

R ³ particularly preferably denotes H or NH ₂ .

R ⁴ is preferably H.

R ⁵ is preferably H.

R ⁶ is preferably H, methyl or ethyl.

n is preferably 0, 1 or 2.

Hal is preferably F, Cl or Br, but also I, more preferably F or Cl.

For the entire invention applies that all the radicals, that occur multiple times, may be the same or different, d. H. are independent of each other. The connections of the Formula I can have one or more chiral centers and therefore occur in different stereoisomeric forms. The Formula I encompasses all these forms.

Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings given above. Some preferred groups of compounds can be expressed by the following partial formulas Ia to Ik, which correspond to the formula I and in which the unspecified radicals have the meaning given in the formula I, wherein however
in Ia R ^{1 is} H, A, COAr or - [C (R ⁶ ) ₂ ] _n Ar,
means;
in Ib R ^{2 is} H;
in Ic R ^{3 is} H or N (R ⁶ ) ₂ ;
in Id R ⁴ denotes H;
in Ie R ^{5 is} H;
in If A is unbranched or branched alkyl having 1-8 C atoms, in which one CH ₂ group may be replaced by oxygen and / or also 1-7 H atoms by F,
means;
unbranched or branched alkyl having 1-6 C atoms in Ig A, in which 1-7 H atoms may be replaced by F,
means;
unsubstituted or mono-, di- or trisubstituted by Hal and / or OR ⁶ in Ih Ar,
means;
in Ii Het an unsubstituted or mono- or di-substituted by A mono- or binuclear aromatic heterocycle having 1 to 4 N-, and / or O and / or S atoms
means;
in Ij Het unsubstituted or mono- or di-substituted by A furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, Quinolyl or 1,3-benzodioxolyl,
means;
in Ik R ¹ H, A, COAr or - [C (R ⁶ ) ₂ ] _n Ar,
R ² H,
R ^{3 is} H or N (R ⁶ ) ₂ ,
R ⁴ H,
R ⁵ H,
R ^{6 is} H or alkyl having 1-6 C atoms,
A is unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,
Ar unsubstituted or mono-, di- or trisubstituted by Hal and / or OR ⁶ phenyl,
n 0, 1 or 2
mean;
and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios.

The Compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as in the literature (eg in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart) are described, under reaction conditions, for the said reactions are known and suitable. It can one also from known, not mentioned here Make use of variants.

links of the formula I can preferably be obtained by Compounds of formula II with a compound of formula III implements. The compounds of formula II and of formula III are usually known. If they are new, they can be prepared by methods known per se.

The Reaction takes place in an inert solvent and takes place usually in the presence of an acid-binding agent preferably an organic base such as DIPEA, triethylamine, dimethylaniline, Pyridine or quinoline.

Also the addition of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other weak acid salt the alkali or alkaline earth metals, preferably potassium, sodium, Calcium or cesium can be cheap.

The Response time varies depending on the conditions used a few minutes and 14 days, the reaction temperature between about -15 ° and 150 °, normally between 40 ° and 130 °, more preferably between 60 ° and 110 ° C.

When inert solvents are suitable for. B. hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers, such as diethyl ether, Diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or Dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of said solvents.

Especially preferred are glycol ethers, such as ethylene glycol monomethyl ether, THF, Dichloromethane and / or DMF.

preferred Protecting groups are for. Sulfonyl protecting groups such as tosyl or mesyl, also protective groups such. BOC.

links of the formula I can furthermore preferably be obtained by reacting compounds of the formula IV and with a compound of the Formula V, translates.

The Compounds of the formula IV and of the formula V are generally known. If they are new, they can be known Methods are produced.

First becomes the compound of formula IV in a Masuda coupling to a Boron compound reacted and the intermediate subsequently implemented in a Suzuki coupling with the compound of formula V.

The reaction takes place in an inert solvent and under conditions as known to those skilled in the art are known for a Masuda and Suzuki coupling.

The Compounds of formulas I can also be obtained by removing them from their functional derivatives by solvolysis, in particular hydrolysis, or freed by hydrogenolysis.

Preferred starting materials for the solvolysis or hydrogenolysis are those which contain, instead of one or more free amino and / or hydroxyl groups, corresponding protected amino and / or hydroxyl groups, preferably those which, instead of an H atom, are bonded to an N atom is to carry an amino protecting group, for. For example, those corresponding to Formula I but containing an NHR 'group (where R' represents an amino-protecting group, e.g., BOC or CBZ) instead of an NH ₂ group.

Further preference is given to starting materials which, instead of the H atom, are a hydroxy group carry a hydroxy protecting group, e.g. For example, those of the formula I. but instead of a hydroxyphenyl group, a R''O-phenyl group (where R "represents a hydroxy protecting group).

It can also be several - same or different - protected Amino and / or hydroxy groups in the molecule of the starting material to be available. If the existing protection groups from each other They are different, they can in many cases be cleaved selectively.

Of the The term "amino protecting group" is well known and refers to groups that are suitable, an amino group to protect (block) from chemical reactions, but are easily removable after the desired chemical reaction performed elsewhere in the molecule has been. Typical of such groups are in particular unsubstituted or substituted acyl, aryl, aralkoxymethyl or Aralkyl groups. Since the amino protecting groups are according to the desired Reaction (or reaction sequence) is their nature and Size otherwise not critical; prefers However, those with 1-20, especially 1-8 C atoms. The term "acyl group" is in the context of the present proceedings in the broadest sense specific. It encloses of aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids derived acyl groups and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such Acyl groups are alkanoyl such as acetyl, propionyl, butyryl; aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; aryloxyalkanoyl like POA; Alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr, Pbf or Pmc. Preferred amino protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.

Of the Term "hydroxy protecting group" is also generic and refers to groups that are suitable for a hydroxy group to protect against chemical reactions, but easy are removable after the desired chemical reaction been performed elsewhere in the molecule is. Typical of such groups are those mentioned above unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. The nature and size The hydroxy protecting group is not critical since it is the desired one chemical reaction or reaction sequence are removed again; preferred are groups having 1-20, in particular 1-10 C-atoms. Examples for hydroxy protecting groups u. a. tert-butoxycarbonyl, Benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, Benzyl and tert-butyl are particularly preferred. The COOH groups in aspartic acid and glutamic acid are preferred protected in the form of their tert-butyl esters (eg Asp (OBut)).

The In-freedom setting of the compounds of formula I from their functional Derivatives succeed - depending on the protective group used - z. B. with strong acids, convenient with TFA or perchloric acid, but also with other strong inorganic Acids such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids such as trichloroacetic acid or sulfonic acids such as benzene or p-toluenesulfonic acid. The presence of an additional inert solvent is possible but not always required. As inert Solvents are preferably organic, for example Carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as Dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, as well as water. Furthermore, mixtures of the aforementioned solvents in question. TFA is preferably in excess without Addition of another solvent used, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9: 1. The reaction temperatures for the cleavage is suitably between about 0 and about 50 °, preferably working between 15 and 30 ° (room temperature).

The groups BOC, OBut, Pbf, Pmc and Mtr can, for. B. preferably with TFA in dichloromethane or with about 3 to 5n HCl are cleaved in dioxane at 15-30 °, the FMOC group with an about 5- to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.

hydrogenolytically removable protecting groups (eg, CBZ or benzyl) can be used z. B. by treatment with hydrogen in the presence of a catalyst (For example, a noble metal catalyst such as palladium, appropriate on a carrier such as coal) are split off. As a solvent are the above specified, in particular z. For example, alcohols such as methanol or ethanol or amides such as DMF. The hydrogenolysis is usually at temperatures between about 0 and 100 ° and Printing between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar performed. A hydrogenolysis of CBZ group succeeds z. B. good at 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) on Pd / C in methanol / DMF at 20-30 °.

Pharmaceutical salts and other forms

The let said compounds of the invention to use in their final non-salt form. on the other hand The present invention also encompasses the use of these Compounds in the form of their pharmaceutically acceptable salts, those of various organic and inorganic acids and Bases can be derived by methods known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are produced mostly conventionally. If the compound of the formula I is a carboxylic acid group contains, can be one of their appropriate Form salts by reacting the compound with a suitable base to give the corresponding base addition salt. Such Bases include, for example, alkali metal hydroxides, including potassium hydroxide, Sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as Barium hydroxide and calcium hydroxide; Alkali metal alcoholates, e.g. B. Potassium ethanolate and sodium propanolate; as well as various organic Bases such as piperidine, diethanolamine and N-methylglutamine. The aluminum salts the compounds of formula I are also included. at certain compounds of formula I can be acid addition salts by forming these compounds with pharmaceutical harmless organic and inorganic acids, eg. As hydrogen halides such as hydrogen chloride, hydrogen bromide or Hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like as well as alkyl and Monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, as well as other organic acids and their corresponding Salts such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, Benzoate, salicylate, ascorbate and the like. Accordingly belong to pharmaceutically acceptable acid addition salts of the compounds of formula I the following: acetate, adipate, alginate, Arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, Bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, Chloride, chlorobenzoate, citrate, cyclopentane propionate, digluconate, Dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, Fumarate, Galacterate (from mucic acid), galacturonate, glucoheptanoate, Gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, Hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, Iodide, isethionate, isobutyrate, lactate, lactobionate, malte, maleate, Malonate, mandelate, metaphosphate, methanesulfonate, methyl benzoate, Monohydrogen phosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, Oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, Phosphate, phosphonate, phthalate, but no limitation represents.

Farther are among the base salts of the invention Compounds aluminum, ammonium, calcium, copper, iron (III) -, Iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, Sodium and zinc salts, but not a limitation should represent. Preferred among the above-mentioned salts Ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts Calcium and magnesium. To salts of the compounds of the formula I, derived from pharmaceutically acceptable non-toxic organic Derive bases, salts include primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic Amines and basic ion exchange resins, eg. Arginine, betaine, Caffeine, chloroprocaine, choline, N, N'-dibenzylethylenediamine (benzathine), Dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, Lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, Piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, Triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl) methylamine (Tromethamine), which are not limiting should.

Compounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C ₁ -C ₄ ) alkyl halides, e.g. Methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; Di (C ₁ -C ₄ ) alkyl sulfates, e.g. For example, dimethyl, diethyl and diamylsulfate; (C ₁₀ -C ₁₈ ) alkyl halides, e.g. Decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl (C ₁ -C ₄ ) alkyl halides, e.g. As benzyl chloride and phenethyl bromide quaternize. With such salts can be both water and oil-soluble compounds of the invention are prepared.

To the abovementioned pharmaceutical salts, which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, Gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, Mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, Stearate, sulphate, sulphosalicylate, tartrate, thiomalate, tosylate and Tromethamine, which is not a limitation should.

The Acid addition salts of basic compounds of the formula I. are prepared by using the free base form with a sufficient amount of the desired acid in contact with it, whereby in the usual way the salt represents. The free base can be brought into contact salt form with a base and isolate the free base to usual Regenerate way. The free base forms differ in certain sense of their corresponding salt forms in relation to certain physical properties such as solubility in polar solvents; in the context of the invention correspond to the Salts, however, otherwise their respective free base forms.

As mentioned are the pharmaceutically acceptable base addition salts the compounds of the formula I with metals or amines such as alkali metals and alkaline earth metals or organic amines. preferred Metals are sodium, potassium, magnesium and calcium. preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, Choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The Base addition salts of acidic according to the invention Compounds are made by using the free Acid form with a sufficient amount of the desired Base brings into contact, making the salt on usual Way. Leave the free acid by contacting the salt form with an acid and isolating the free acid in a conventional manner regenerate. The free acid forms differ in a sense, of their corresponding salt forms in relation to certain physical properties such as solubility in polar solvents; correspond within the scope of the invention the salts, however, otherwise their respective free acid forms.

contains a compound of the invention more than one Group which can form such pharmaceutically acceptable salts, thus, the invention also encompasses multiple salts. To typical multiple salt forms include, for example, bitartrate, diacetate, Difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this should not be a limitation.

in the In view of the above, it can be seen that under the Expression "pharmaceutically acceptable salt" in The present context is understood to mean an active substance which has a Contains compound of formula I in the form of one of its salts, especially if this salt form compared to the active ingredient to the free form of the active ingredient or any other salt form the active ingredient used previously improved pharmacokinetic properties. The pharmaceutically acceptable Salt form of the drug can also be a desired confer pharmacokinetic properties on which it used to be did not dispose of, and may even have the pharmacodynamics of this Active substance in terms of its therapeutic efficacy in the body influence positively.

object The invention furthermore relates to medicaments containing at least one Compound of the formula I and / or its pharmaceutically usable derivatives, Solvates and stereoisomers, including mixtures thereof in all circumstances, as well as, if applicable, carrier and / or auxiliaries.

pharmaceutical Formulations may take the form of dosage units containing a contain predetermined amount of active ingredient per unit dose, presented become. Such a unit may for example be 0.5 mg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg contain a compound of the invention, depending on the condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical Formulations may take the form of dosage units containing a contain predetermined amount of active ingredient per unit dose, presented become. Preferred unit dosage formulations are those the one daily dose or partial dose as stated above or a corresponding one Fraction of it containing an active ingredient. You can continue Such pharmaceutical formulations with one of the pharmaceutical Fachgebiet generally produce known method.

Pharmaceutical formulations may be administered by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) routes. Such formulations can be prepared by any method known in the pharmaceutical art, for example, by bringing the active ingredient together with the carrier (s) or excipient (s).

At the oral administration adapted pharmaceutical formulations can be used as separate units, such as B. capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or nonaqueous liquids; Eatable Foams or foam foods; or oil-in-water liquid emulsions or Water-in-oil liquid emulsions are presented.

So can be, for example, in oral administration in the form of a tablet or capsule, the active component with a oral, non-toxic and pharmaceutically acceptable inert Carrier, such. As ethanol, glycerol, water u. ä. combine. Powders are made by adding the compound to a suitable fine size crushed and with a similarly, pharmaceutical excipient, such as As an edible carbohydrate such as Starch or mannitol is mixed. A flavor, Preservative, dispersant and dye also be present.

capsules are prepared by mixing a powder mixture as described above made and shaped gelatin shells filled with it become. Lubricants and lubricants such. B. fumed silica, Talc, magnesium stearate, calcium stearate or polyethylene glycol In solid form, the powder mixture before the filling process be added. An explosive or solubilizer, such as As agar-agar, calcium carbonate or sodium carbonate, can also be added to the availability of the drug to improve after ingestion of the capsule.

Furthermore may, if desired or necessary, appropriate Binders, lubricants and disintegrants, as well as dyes be incorporated into the mixture. To the suitable binders include starch, gelatin, natural Sugar, such as As glucose or beta-lactose, sweeteners from corn, natural and synthetic gums, such as B. Acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, Waxes, u. Ä. To those used in these dosage forms Lubricants include sodium oleate, sodium stearate, magnesium stearate, Sodium benzoate, sodium acetate, sodium chloride and the like. Ä. To The explosives include, but are not limited to starch, methylcellulose, agar, bentonite, xanthan gum u. Ä. The tablets are formulated by, for example a powder mixture is prepared, granulated or dry-pressed, a lubricant and a disintegrant are added and the Whole is pressed into tablets. A powder mixture is prepared by the suitably comminuted compound with a diluent or a base, as described above, and optionally with a binder, such as. Carboxymethylcellulose, an alginate, gelatin or polyvinylpyrrolidone, a slows dissolver, such as As paraffin, a resorption accelerator, such as. B. one quaternary salt and / or an absorbent, such as z. As bentonite, kaolin or dicalcium phosphate is mixed. The Powder mixture can be granulated by adding with a binder, such as. Syrup, starch paste, Acadia mucus or wetting solutions of cellulosic or polymeric materials and pressed through a sieve. As an alternative to granulation you can run the powder mixture through a tabletting machine leave unevenly formed lumps, which are broken up into granules. The granules can by adding stearic acid, a stearate salt, talc or mineral oil to be greased to stick to the tablet molds to prevent. The greased mixture is then compressed into tablets. The compounds of the invention may also combined with a free-flowing inert carrier and then without performing the granulation or dry compression steps be pressed directly into tablets. A transparent one or opaque protective layer, consisting of a seal made of shellac, a layer of sugar or polymer material and a glossy layer of wax, may be present. These coatings Dyes can be added to differentiate between To be able to distinguish dosage units.

oral Liquids, such. Solution, syrups and elixirs, can be prepared in the form of dosage units, so that a given quantity is a given Amount of the compound contains. Syrups can be prepared, by placing the compound in an aqueous solution with appropriate taste is dissolved while Elixir using a non-toxic alcoholic vehicle getting produced. Suspensions can be by dispersion of the compound in a non-toxic vehicle. Solubilizers and emulsifiers, such. B. ethoxylated Isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, Flavor additives, such as. B. peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, u. ä. can also be added.

The unit dosage formulations for oral administration may optionally be encapsulated in microcapsules. The formulation can also be prepared to prolong the release or retarded, such as by coating or embedding particulate material in polymers, wax, and the like. ä.

The Compounds of formula I and salts, solvates and physiological functional derivatives thereof can also be in the form of liposome delivery systems, such as Small unilamellar vesicles, large unilamellar ones Vesicles and multilamellar vesicles, administer.

liposomes can be made of different phospholipids, such as. Cholesterol, Stearylamine or phosphatidylcholines are formed.

The Compounds of the formula I and the salts, solvates and physiological functional derivatives thereof may also be used monoclonal antibody as an individual carrier, to which the compound molecules are coupled, fed become. The compounds can also be soluble Polymers coupled as targeted drug carrier become. Such polymers may include polyvinylpyrrolidone, pyran copolymer, Polyhydroxypropylmethacrylamidephenol, Polyhydroxyethylaspartamidphenol or polyethylene oxide polylysine substituted with palmitoyl radicals, include. Furthermore, the connections to a class of biodegradable polymers used to obtain a controlled Release of a drug are suitable, for. B. polylactic acid, Polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoester, Polyacetals, polydihydroxypyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches for prolonged, intimate contact with the epidermis of the recipient. For example, the drug can be delivered from the patch by iontophoresis, as in Pharmaceutical Research, 3 (6), 318 (1986) generally described.

At the topical administration adapted pharmaceutical compounds can be used as ointments, creams, suspensions, lotions, powders, Solutions, pastes, gels, sprays, aerosols or oils be formulated.

For Treatments of the eye or other external tissues, z. As mouth and skin, the formulations are preferably as applied topical ointment or cream. When formulated into a Ointment may be the active ingredient with either a paraffinic or an ointment a water-miscible cream base can be used. alternative The active ingredient can be a cream with an oil-in-water cream base or a water-in-oil basis.

To the adapted to the topical application to the eye pharmaceutical Formulations include eye drops, where the active ingredient in a suitable carrier, in particular an aqueous Solvent, dissolved or suspended.

At the topical application in the mouth adapted pharmaceutical Formulations include lozenges, lozenges and mouthwashes.

At rectal administration adapted pharmaceutical formulations can be in the form of suppositories or enemas be presented.

At the nasal administration adapted pharmaceutical formulations, in which the carrier is a solid a coarse powder with a particle size, for example in the range of 20-500 microns that in the way as snuff is absorbed, d. H. by Quick inhalation via the nasal passages from a close to the nose held container with the powder. suitable Formulations for administration as a nasal spray or nose drops comprising a liquid as a carrier substance Active substance solutions in water or oil.

At administration by inhalation adapted pharmaceutical Formulations include fine particulate dusts or nebulae, which are pressurized by means of various types Dosing dispensers with aerosols, nebulizers or insufflators produced can be.

At the vaginal administration adapted pharmaceutical formulations Can be used as pessaries, tampons, creams, gels, pastes, foams or spray formulations are presented.

Included among the pharmaceutical formulations adapted for parenteral administration aqueous and non-aqueous sterile injection solutions containing anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickeners. The formulations may be administered in single or multiple dose containers, e.g. As sealed ampoules and vials, and are stored in freeze-dried (lyophilized) state, so that only the addition of the sterile carrier liquid, eg. As water for injections, immediately before use is required. Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.

It It is understood that the formulations in addition to the above particularly mentioned constituents others common in the art Means with respect to the respective type of formulation included can; for example, for the oral administration suitable formulations flavorings contain.

A therapeutically effective amount of a compound of formula I depends depends on a number of factors, including B. the Age and weight of the animal, the exact disease state, the the treatment needs, as well as its severity, the condition the formulation as well as the route of administration, and ultimately will determined by the attending physician or veterinarian. However, it lies an effective amount of a compound of the invention for the treatment of neoplastic growth, e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg Body weight of the recipient (mammal) per day and more typically in the range of 1 to 10 mg / kg of body weight per day. Thus, would be for a 70 kg adult Mammals the actual amount per day for usually between 70 and 700 mg, this amount being Single dose per day or more commonly in a series of divided doses (such as two, three, four, five or six) per day can be so that the total daily dose is the same. A effective amount of a salt thereof may be used as a proportion of the effective Amount of the compound of the invention per se be determined. It can be assumed that similar Dosages for the treatment of the other, mentioned above Disease conditions are suitable.

object The invention further comprises medicaments containing at least one Compound of formula I and / or its pharmaceutically acceptable Salts and stereoisomers, including mixtures thereof in all proportions, and at least one other drug.

• (a) einer wirksamen Menge an einer Verbindung der Formel I und/oder ihrer pharmazeutisch verwendbaren Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und
• (b) einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs.

The invention is also a set (kit), consisting of separate packages of

• (a) an effective amount of a compound of formula I and / or its pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all proportions, and
• (b) an effective amount of another drug.

The Set contains suitable containers, such as boxes or cartons, individual bottles, bags or ampoules. The set can z. B. separate ampoules contain, in each of which an effective Amount of a compound of the formula and / or its pharmaceutical usable salts and stereoisomers, including theirs Mixtures in all proportions, and effective Amount of another active pharmaceutical ingredient dissolved or in lyophilized form.

USE

The Present compounds are useful as pharmaceutical agents for mammals, in particular for the People in the treatment and control of cancer.

The The present invention includes the use of the compounds of Formula I and / or their physiologically acceptable salts for the preparation a medicine for the treatment or prevention of cancer. preferred Carcinomas for treatment come from the brain cancer group, Urogenital tract carcinoma, carcinoma of the lymphatic system, gastric carcinoma, Laryngeal carcinoma and lung carcinoma colon cancer. Another group preferred forms of cancer are monocytic leukemia, lung adenocarcinoma, small cell Lung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma.

Also included is the use of the compounds of the formula I and / or their physiologically acceptable salts for the manufacture of a medicament for the treatment and / or control of a tumor-related disease in a mammal, which method is intended for a sick mammal in need of such treatment. administered a therapeutically effective amount of a compound of the invention. The therapeutic amount depends on the particular disease and can be determined by a person skilled in the art be determined without any great effort.

Especially preferred is the use for treating a disease wherein the disease is a solid tumor.

Of the solid tumor is preferably selected from the group tumors of squamous epithelium, bladder, stomach, kidneys, of the head and neck, the esophagus, the cervix, of the thyroid, intestine, liver, brain, the Prostate, genitourinary tract, lymphatic system, stomach, of the larynx and / or the lungs.

Of the solid tumor is further preferably selected from the Group lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, Glioblastomas, colon carcinoma and breast carcinoma.

Farther preferred is the use for treating a tumor of the blood and immune system, preferably selected for the treatment of a tumor from the group of acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and / or chronic lymphocytic leukemia.

object The invention furthermore relates to the use of the invention Compounds for the treatment of bone pathologies, where the bone pathology from the group osteosarcoma, osteoarthritis and rickets.

The Compounds of the formula I can also be used together with others well-known therapeutics due to their respective suitability selected for the condition being treated become.

The Present compounds are also suitable for combination with known Anticancer agents. These include known anticancer agents the following: estrogen receptor modulators, androgen receptor modulators, Retinoid receptor modulators, cytotoxic agents, antiproliferative agents, Prenyl protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, Reverse transcriptase inhibitors and other angiogenesis inhibitors. The Present compounds are particularly suitable for common Application with radiotherapy. "Estrogen receptor modulators" refers refers to compounds that bind to estrogen interfere with or inhibit the receptor, independently of how this happens. To the estrogen receptor modulators include, for example, tamoxifen, raloxifene, idoxifen, LY353381, LY117081, toremifene, fulvestrant, 4- [7- (2,2-dimethyl-1-oxopropoxy-4-methyl-2- [4- [2- (1-piperidinyl) ethoxy] phenyl] -2H-1-benzopyrano- 3-yl] -phenyl-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646, which however, should not be limiting.

Refers to "androgen receptor modulators" focus on compounds that bind to androgens to the receptor disturb or inhibit, regardless of how this happens. Include androgen receptor modulators for example finasteride and other 5α-reductase inhibitors, Nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate.

Refers to "retinoid receptor modulators" refers to compounds that inhibit the binding of retinoids to the receptor disturb or inhibit, regardless of how this happens. To such retinoid receptor modulators include, for example, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α-difluoromethylornithine, ILX23-7553, trans-N- (4'-hydroxyphenyl) retinamide and N-4-carboxyphenylretinamide.

Refers to "cytotoxic agents" focus on compounds primarily through direct exposure on cell function lead to cell death or cell myosis inhibit or disturb these, including alkylating agents, Tumor necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.

The cytotoxic agents include, for example, tirapazimine, Sertenef, cachectin, ifosfamide, tasonermine, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcite, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improvisulfan-tosylate, trofosfamide, nimustine, dibrospidium chloride, Pumitepa, Lobaplatin, Satraplatin, Profiromycin, Cispiatine, Irofulvene, Dexifosfamide, cis-Amine dichloro (2-methylpyridine) platinum, Benzylguanine, Glufosfamide, GPX100, (trans, trans, trans) -bis-mu (hexane-1.6 -diamine) -mu [diamine-platinum (II)] bis [diamine (chloro) -platinum (II)] - tetrachloride, diarizidinylspermine, arsenic trioxide, 1- (11-dodecylamino-10-hydroxyundecyl) -3,7-dimethylxanthine, zorubicin , Idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafid, valrubicin, amrubicin, antineoplaston, 3'-desamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, Annamycin, galarubicin, elinafide, MEN10755 and 4-desmethoxy-3-desamino-3-aziridinyl-4-methylsulfonyl daunorubicin (see WO 00/50032 ), which should not be limiting.

To the microtubulin inhibitors include, for example, paclitaxel, Vindesine sulfate, 3 ', 4'-dideshydro-4'-deoxy-8'-norvincaleukoblastin, Docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, Cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N- (3-fluoro-4-methoxyphenyl) benzenesulfonamide, Anhydrovinblastine, N, N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797. Topoisomerase inhibitors are for example topotecan, Hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3 ', 4'-O-exo-benzylidene-chartreusine, 9-Methoxy-N, N-dimethyl-5-nitropyrazolo [3,4,5-kl] acridine-2- (6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9 -hydroxy-4-methyl-1H, 12H-benzo [de] pyrano [3 ', 4': b, 7] indolizino [1,2b] quinoline-10,13 (9H, 15H) -dione, Lurtotecan, 7- [2- (N-isopropylamino) ethyl] - (20S) camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide-phosphate, teniposide, sobuzoxan, 2'-dimethylamino-2'-deoxy-etoposide, GL331, N- [2- (dimethylamino) ethyl] -9-hydroxy-5,6-dimethyl-6H-pyrido [4,3-b] carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa, 9b) -9- [2- [N- [2- (dimethylamino) ethyl] -N-methylamino] ethyl] -5- [4-hydroxy-3,5-dimethoxyphenyl] -5,5a, 6,8,8a, 9 -hexohydrofuro (3 ', 4': 6,7) naphtho (2,3-d) -1,3-dioxol-6-one, 2,3- (methylenedioxy) -5-methyl-7-hydroxy-8-methoxybenzo [c] phenanthridinium, 6,9-bis [(2-aminoethyl) amino] benzo [g] isoquinoline-5,10-dione, 5- (3-aminopropylamino) -7,10-dihydroxy-2- (2-hydroxyethylaminomethyl) -6H-pyrazolo [4,5,1-de] acridin-6-one, N- [1- [2 (diethylamino) ethylamino] -7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl] formamide, N- (2- (dimethylamino) ethyl) acridine-4-carboxamide, 6 - [[2- (dimethylamino) ethyl] amino] -3-hydroxy-7H-indeno [2,1-c] quinoline 7-on and Dimesna.

Antiproliferative agents include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabinocfosfate, Fosteabin Sodium Hydrate, Raltitrexed, Paltitrexide, Emitefur, Tiazofurin, Decitabine, Nolatrexed, Pemetrexed, Nelzarabine, 2'-Deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N- [5- (2,3- Dihydrobenzofuryl) sulfonyl] -N '- (3,4-dichlorophenyl) urea, N6- [4-deoxy-4- [N 2 - [2 (E), 4 (E) -tetradecadienoyl] -glycylamino] -L-glycero-BL -manno-heptopyranosyl] adenine, aplidine, ecteinascidin, troxacitabine, 4- [2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino [5,4-b] [1,4] thiazine -6-yl- (S) -ethyl] -2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8- (carbamoyloxymethyl) -4-formyl-6-methoxy-14- oxa-1,11-diazatetracyclo (7.4.1.0.0) -tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexo l, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-BD-arabinofuranosylcytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The "antiproliferative agents" also include other monoclonal antibodies against growth factors than those already listed under the "angiogenesis inhibitors", such as Trastuzu mab, as well as tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see e.g. U.S. Patent No. 6,069,134 ).

Proof of pharmacological effect Inhibitors on the proliferation / vitality of tumor cells in vitro

1.0 Background

In The present study describes the inhibition of tumor cell proliferation / tumor cell vitality described by active ingredients.

The Cells are in suitable cell density in microtiter plates (96-well Format) and the test substances are in the form added to a concentration series. After four more days the Culture in serum-containing medium may include tumor cell proliferation / tumor cell vitality be determined by means of an Alamarblue test system.

2.0 experimental procedure

2.1 cell culture

For example commercially available colon carcinoma cell lines, Ovarian cell lines, prostate cell lines or cell lines the breast etc.

The cells are cultured in medium. At intervals of several days, the cells are detached from the culture dishes with the aid of trypsin solution and diluted at appropriate dilution in fresh medium sown. The cells are cultured at 37 ° C and 10% CO ₂ .

2.2. Sowing the cells

A defined cell number (eg 2000 cells) are per culture / well in a volume of 180 μl of culture medium in microtiter plates (96-well cell culture plates) seeded with a multichannel pipette. The cells are then placed in a CO2 incubator (37 ° C and 10% CO2).

2.3. Addition of the test substances

The test substances are dissolved, for example, in DMSO and then used in the cell culture medium in appropriate concentration (optionally a dilution series). The dilution levels can be adjusted depending on the efficiency of the active ingredients and the desired spread of the concentrations. The test substances are mixed in appropriate concentrations with cell culture medium. The addition of the test substances to the cells can take place on the same day as the sowing out of the cells. For this purpose, 20 μl of the substance solution is added to the cultures / wells from the predilution plate. The cells are cultured for a further 4 days at 37 ° C and 10% CO ₂ .

2.4. Measurement of the color reaction

Per well, 20 μl AlamarBlue reagent are added and For example, the microtiter plates are used for more seven hours in a CO2 incubator (at 37 ° C and 10% CO2). The plates are attached to a reader with a fluorescence filter measured at a wavelength of 540 nm. The plates can shake lightly just before the measurement become.

3. Evaluation

The absorbance value of the medium control (no use of cells and test substances) is subtracted from all other extinction values. The controls (cells without test substance) are set equal to 100 percent and all other extinction values are related to this (expressed as% of control, for example): Invoice:

The determination of IC ₅₀ values (50% inhibition) is carried out with the aid of statistical programs such. B. RS1.

• APCI-MS (atmospheric Pressure chemical ionization – mass spectrometry) (M+H)⁺.

IC ₅₀ data of compounds according to the invention are given in Table 1. material Order no. Manufacturer Microtiter plates for cell culture (Nunclon Surface 96-well Plate) 167008 Nunc DMEM P04-03550 Pan Biotech PBS (10 ×) Dulbecco 14200-067 Gibco 96-well plates (polypropylene) 267334 Nunc AlamarBlue ^TM BUF012B Serotec FCS 1302 Pan Biotech GmbH Trypsin / EDTA Solution 10 × L 2153 Biochrom AG 75 cm ² culture bottles 353136 BD Falcon A2780 93112519 ECACC Colo205 CCL222 ATCC MCF7 HTB22 ATCC PC3 CRL-1435 ATCC

• APCI-MS (atmospheric pressure chemical ionization - mass spectrometry) (M + H) ⁺ .

HPLC gradient

Pillar:

• Chromolith Performance RP-18e (Merck KGaA, Cat 1.02129.0001)

eluent:

• Eluent A: 0.1 M aq. NaH2PO4
• Eluent B: acetonitrile + 10% water
• Flow rate: 4 ml / min

Gradient:

• 0 min 1% B
• 1 min 1% B
• 7 min 99% B
• 8 min 99% B

example 1

The preparation of 4- (1H-pyrrolo [2,3-b] pyridin-3-yl) -pyridin-2-ylamine ("A1") is carried out analogously to the scheme below

A solution of 35 mg (0.03 mmol) of tetrakis (triphenylphosphine) -palladium and 344 mg (1.00 mmol) of tert-butyl-3-iodo (1H) -pyrrolo [2,3-b] pyridine-1-carboxylate in nitrogen 5 ml of dioxane are mixed successively with 0.42 ml (3.00 mmol) of triethylamine and 0.22 ml (1.5 mmol) of 4,4,5,5-tetramethyl-1,3,2-dioxaborolane and the mixture is stirred under nitrogen at 80 ° C. for 3 hours , The reaction mixture is cooled to room temperature; 5 ml of methanol, 173 mg (1.0 mmol) of 4-bromopyridine-2-amine and 823 mg (2.5 mmol) of cesium carbonate are added successively. The reaction mixture is stirred for 18 hours at 100.degree. Allow to cool to room temperature and partition the reaction mixture between dichloromethane and water. The organic phase is dried over sodium sulfate, evaporated and chromatographed on a silica gel column with dichloromethane / methanol / dilute aqueous ammonia as eluent: 4- (1H-pyrrolo [2,3-b] pyridin-3-yl) -pyridin-2-ylamine ("A1") as yellow crystals; ESI 211;
¹ H-NMR (DMSO-d ₆ ): δ [ppm] = 5.85 (s, 2H), 6.86 (d, J = 5.4 Hz, 1H), 6.88 (s, 1H), 7.19 (dd, J ₁ = 8.2 Hz, J ₂ = 4.7 Hz, 1H), 7.90 (d, J = 5.4 Hz, 1H), 8.00 (d, J = 1.9 Hz, 1H), 8.29 (d, J = 4.7 Hz, 1H), 8.32 (i.e. , J = 8.2 Hz, 1H), 12.1 (bs, 1H).

Analogously, the following compounds are obtained

durchgeführt nach A. Jozwiak et al., Eur. J. Org. Chem. 2004, 3254 ;

durchgeführt nach J. Zhang et al., Synlett 2001, 643 .The required bromopyridine derivatives for the production of "A8" to "A10" are prepared according to the following schemes:

performed after A. Jozwiak et al., Eur. J. Org. Chem. 2004, 3254 ;

performed after J. Zhang et al., Synlett 2001, 643 ,

Example 2

The Preparation of Butyl [4- (1H-Pyrrolo [2,3-b] pyridin-3-yl) -pyridin-2-yl] -amine ("A3")

A solution of 371 mg (2.00 mmol) of 4-bromo-2-fluoropyridine and 299 mg (4.0 mmol) of n-butylamine in 2 ml of pyridine are heated to 100 ° C. for 21 hours in a closed pressure tube. The reaction mixture is cooled to room temperature, treated with 5 ml of water and extracted several times with dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated in vacuo. The residue is chromatographed on a silica gel column with petroleum ether / ethyl acetate 7: 1 as Laufmttel: 4-bromo-N-butylpyridin-2-amine as a yellow solid;
¹ H-NMR (CDCl ₃ ): δ [ppm] = 0.95 (t, J = 7.6 Hz, 3H), 1.42 (sextet, J = 7.6 Hz, 2H), 1.60 (quintet, 7.6 Hz, 2H), 3.19- 3.25 (m, 2H), 4.6 (bs, 1H), 6.53 (d, J = 1.6 Hz, 1H), 6.70 (dd, J = 5.4 Hz, J = 1.6 Hz, 1H), 7.88 (d, J = 5.4 Hz, 1H).

The Reaction is performed as described for "A1" (see Example 1).

Butyl [4- (1H-pyrrolo [2,3-b] pyridin-3-yl) -pyridin-2-yl] amine ("A3") is obtained as a pale yellow solid; ESI 267;
¹ H-NMR (DMSO-d ₆ ): δ [ppm] = 0.92 (t, J = 7.6 Hz, 3H), 1.39 (sextet, J = 7.6 Hz, 2H), 1.51-1.58 (m, 2H), 3.25 -3.31 (m, 2H), 6.40 (t, J = 5.4 Hz, 1H) 6.83 (dd, J = 5.4 Hz, J = 1.6 Hz, 1H), 6.87-6.89 (m, 1H), 7.19 (dd, J = 7.9 Hz, J = 4.7 Hz, 1H), 7.95 (d, J = 5.4 Hz, 1H), 8.01 (d, J = 2.5 Hz, 1H), 8.30 (dd, J = 7.4 Hz, J = 1.3 Hz, 1H), 8.34 (dd, J = 7.9 Hz, J = 1.3 Hz, 1H), 12.1 (bs, 1H).

Analogously, the following compounds are obtained

Example 3

• Literatur: J. Yin et al., Organic Letters 2002, Vol. 4, 3481 .

The connections "A4" to "A7" can alternatively be made from "A1" as follows: 3.1 Implementation of "A1" to "A4":

• Literature: J. Yin et al., Organic Letters 2002, Vol. 4, 3481 ,

Example 4

• Literatur: J. Yin et al., Organic Letters 2002, Vol. 4, 3481 .

Tabelle 1 Inhibierung auf die Proliferation/Vitalität von Tumorzellen IC₅₀ von erfindungsgemäßen Verbindungen Verbindung Nr. IC₅₀ Zellen A2780 (Eierstock) ”A1” A ”A2” A IC₅₀: 10 nM–1 μM = A 1 μM–10 μM = B > 10 μM = C The compounds "A4" to "A7" can alternatively be prepared from 3- (2-chloropyridin-4-yl) -1H-pyrrolo [2,3-b] pyridine as follows: 4.1 Reaction of 3- (2-chloro) pyridin-4-yl) -1H-pyrrolo [2,3-b] pyridine to "A4":

• Literature: J. Yin et al., Organic Letters 2002, Vol. 4, 3481 ,

TABLE 1 Inhibition on the proliferation / vitality of tumor cells IC ₅₀ of compounds according to the invention Connection no. IC ₅₀ cells A2780 (ovary) "A1" A "A2" A IC ₅₀ : 10 nM-1 μM = A 1 μM-10 μM = B > 10 μM = C

The The following examples refer to drugs:

Example A: Injection glasses

A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of bidistilled water with 2N hydrochloric acid, sterile filtered, abge in injection jars abge filled, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.

Example B: Suppositories

you melts a mixture of 20 g of an active ingredient of the formula I with 100 g soy lecithin and 1400 g cocoa butter, pour into molds and lets cool. Each suppository contains 20 mg of active ingredient.

Example C: Solution

A solution of 1 g of an active ingredient of the formula I, 9.38 g of NaH ₂ PO ₄ .2H ₂ O, 28.48 g of Na ₂ HPO ₄ .12H ₂ O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water is prepared , Adjust to pH 6.8, make up to 1 liter and sterilize by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

you mixes 500 mg of an active ingredient of the formula I with 99.5 g Vaseline under aseptic conditions.

Example E: Tablets

One Mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is in the usual Pressed into tablets, so that each Tablet contains 10 mg of active ingredient.

Example F: dragees

Analogous Example E tablets are pressed, which subsequently in the usual way with a coating of sucrose, Potato starch, talc, tragacanth and dye coated become.

Example G: Capsules

2 kg of active ingredient of the formula I are in the usual way in hard gelatin capsules filled so that each capsule contains 20 mg of the active ingredient contains.

Example H: Ampoules

A Solution of 1 kg of active ingredient of the formula I in 60 l in duplicate distilled water is filtered sterile, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each vial contains 10 mg of active ingredient.

QUOTES INCLUDE IN THE DESCRIPTION

This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.

Cited patent literature

• WO 2006/050076 [0005]
• WO 00/50032 [0122]
• - US 6069134 [0124]

Cited non-patent literature

• PM Fresneda et al. in Tetrahedron 57 (2001) 2355-2363 [0005]
• - Int. J. Pharm. 115, 61-67 (1995) [0022]
• Pharmaceutical Research, 3 (6), 318 (1986) [0094]
• - Jozwiak et al., Eur. J. Org. Chem. 2004, 3254 [0138]
• - J. Zhang et al., Synlett 2001, 643 [0138]
• J. Yin et al., Organic Letters 2002, Vol. 4, 3481 [0143]
• J. Yin et al., Organic Letters 2002, Vol. 4, 3481 [0144]

Claims (22)

Compounds of the formula I

wherein R ^{1 is} H, A, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _n cycloalkyl, COA, COAr, CON (R ⁶ ) ₂ or CON (R ⁶ ) Ar, R ² H, A or - [C (R ⁶ ) ₂ ] _n Ar, R ³ H, A, OR ⁶ , N (R ⁶ ) ₂ , - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _n cycloalkyl, O [C (R ⁶ ) ₂ ] _n N (R ⁶ ) ₂ or O [ C (R ⁶ ) ₂ ] _n Het, R ⁴ H, A, Hal, CN, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _n Het, - [C (R ⁶ ) ₂ ] _{n is} cycloalkyl, OR ⁶ or N (R ⁶ ) ₂ R ^{5 is} H or alkyl having 1-6 C atoms, R ^{6 is} H or alkyl having 1-6 C atoms, A is unbranched or branched alkyl having 1-10 C atoms in which one or two CH ₂ groups can be replaced by O or S atoms and / or by -CH = CH groups and / or also 1-7 H atoms by F, cycloalkyl cyclic alkyl with 3 -7 C atoms, which may additionally be substituted by alkyl having 1-6 C atoms, Hal F, Cl, Br or I, Ar unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ⁶ , N ( R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ⁶ COA, NR ⁶ SO ₂ A, COR ⁶ , SO ₂ N (R ⁶ ) ₂ and / or S (O) _p A is substituted phenyl, Het is an unsubstituted or mono- or disubstituted by Hal, A, OR ⁶ , N (R ⁶ ) ₂ , NO ₂ , CN, COOR ⁶ , CON (R ⁶ ) ₂ , NR ⁶ COA, NR ⁶ SO ₂ A, COR ⁶ , SO ₂ NR ⁶ , S (O) _p A and / or = O (carbonyl oxygen) substituted mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N-, and / or O and / or S atoms, n is 0, 1, 2, 3 or 4, p is 0, 1 or 2, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Compounds according to claim 1, wherein R ^{1 represents} H, A, COAr or - [C (R ⁶ ) ₂ ) _n Ar, as well as their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions. Compounds according to claim 1 or 2, wherein R ^{2 is} H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Compounds according to claim 1, 2 or 3, wherein R ^{3 is} H or N (R ⁶ ) ₂ , and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all proportions. Compounds according to one or more of claims 1-4, wherein R ⁴ signifies H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including their Mi in all circumstances. Compounds according to one or more of claims 1-5, wherein R ^{5 is} H, and their pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Compounds according to one or more of claims 1-6, wherein A is unbranched or branched alkyl having 1-8 C atoms, in which one CH ₂ group may be replaced by oxygen and / or also 1-7 H atoms by F. , as well as their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Compounds according to one or more of the claims 1-7, in which A is unbranched or branched alkyl with 1-6 C atoms, in which 1-7 H atoms may be replaced by F, means such as their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all Conditions. Compounds according to one or more of claims 1-7, wherein Ar is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and / or OR ⁶ , as well as their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all circumstances. Compounds according to one or more of the claims 1-9, in which Het an unsubstituted or one or mono- or binuclear aromatic heterocycle which is substituted twice by A with 1 to 4 N, and / or O and / or S atoms, means such as their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all Conditions. Compounds according to one or more of the claims 1-10, in which Het unsubstituted or one or two times A substituted furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, Oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, Tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, Benzimidazolyl, indazolyl, quinolyl or 1,3-benzodioxolyl, means such as their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all Conditions. Compounds according to one or more of claims 1-10, wherein R ^{1 is} H, A, COAr or - [C (R ⁶ ) ₂ ] _n Ar, R ² H, R ³ H or N (R ⁶ ) ₂ , R ⁴ H R ^{5 is} H, R ^{6 is} H or alkyl having 1-6 C atoms, A is unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F, Ar is unsubstituted or mono-, phenyl which is substituted twice or three by Hal and / or OR ⁶ , n is 0, 1 or 2, and their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Compounds according to claim 1, selected from the group

and their pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers, including mixtures thereof in all ratios. Process for the preparation of compounds of the formula I according to Claims 1-13 and their pharmaceutically usable salts, tautomers and stereoisomers, characterized in that a) a compound of the formula II

where R is a protective group, R ³ , R ⁴ and R ^{5 have} the meanings given in claim 1, with a compound of formula III R ¹ -NH ₂ III wherein R ^{1 is} A, - [C (R ⁶ ) ₂ ] _n Ar, - [C (R ⁶ ) ₂ ] _{n is} cycloalkyl or - [C (R ⁶ ) ₂ ] _n Het, and Ar, cycloalkyl, Het, R ⁶ and n have the meanings given in claim 1, and simultaneously or subsequently the protective group R is split off, or b) a compound of the formula IV

wherein R is a protecting group, R ⁴ and R ^{5 have} the meanings given in claim 1, first reacted in a Masuda coupling to a boron compound and then in a Suzuki coupling with a compound of formula V

wherein R ¹ and R ^{3 have} the meanings given in claim 1, and simultaneously or subsequently the protective group R is split off, and / or converts a base or acid of the formula I into one of its salts. Medicament containing at least one compound of the formula I according to claims 1-13 and / or their pharmaceutically usable salts, tautomers and stereoisomers, including their mixtures in all proportions, and optionally Carrier and / or auxiliaries. Use of compounds according to claims 1-13 and their pharmaceutically acceptable salts, tautomers and stereoisomers, including their mixtures in all proportions, for the manufacture of a medicament for the treatment of tumors, Tumor growth, tumor metastasis and / or AIDS. Use according to claim 16, wherein the tumor is group of tumors of squamous epithelium, bladder, stomach, of the kidneys, of the head and neck, of the esophagus, of the cervix, of the thyroid, intestine, liver, brain, the Prostate, genitourinary tract, lymphatic system, stomach, of the larynx and / or lungs. Use according to claim 16, wherein the tumor is the group monocytic leukemia, lung adenocarcinoma, small cell Lung carcinoma, pancreatic cancer, colon carcinoma, Glioblastoma and / or breast carcinoma. Use according to claim 16, which is a Tumor of the blood and immune system acts. Use according to claim 16, wherein the tumor is the group of acute myelotic leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and / or chronic lymphocytic leukemia. Use of compounds of the formula I according to claim 1-13 and / or their physiologically acceptable salts for the manufacture of a medicament for the treatment of tumors, wherein a therapeutically effective amount of a compound of formula I in combination with a compound from the group 1) estrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors, 9) reverse transcriptase inhibitors and 10) other angiogenesis inhibitors. Use of compounds of the formula I according to claim 1-13 and / or their physiologically acceptable salts for the manufacture of a medicament for the treatment of tumors a therapeutically effective amount of a compound of formula I in combination with radiotherapy and a compound from the group 1) estrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative Agent, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors, 9) reverse transcriptase inhibitors, and 10) another angiogenesis inhibitor is administered.